DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Piramal Pharma Limited — Updates

NSE 3 hrs ago·10 Aug 2026, 12:39 pm

Piramal Pharma

Piramal Pharma Limited has exercised a call option to acquire an additional equity stake in its subsidiary, Yapan Bio Private Limited. This move indicates the parent company's intent to deepen its control over this specific business unit.

For investors, this development signals a strategic focus on strengthening the operational capabilities and market position of Yapan Bio. It suggests that the company views this particular segment as a key growth area within its broader portfolio.

Investors should monitor the financial implications of this acquisition, including any potential impact on the group's overall profitability. Keeping an eye on future operational synergies will be important to gauge the long-term value of this expansion.